Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

257.01 +6.76 (+2.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Insulet to Announce Second Quarter 2024 Financial Results on August 8, 2024
From Insulet Corporation
Via Business Wire
(PODD) - Analyzing Insulet's Short Interest
Via Benzinga
Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.
INSULET CORP (NASDAQ:PODD), a strong growth stock, setting up for a breakout. 
Via Chartmill
Insulet’s SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes
From Insulet Corporation
Via Business Wire
$1000 Invested In Insulet 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Looking Into Insulet's Recent Short Interest
Via Benzinga
Where Insulet Stands With Analysts
Via Benzinga
Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands
From Insulet Corporation
Via Business Wire
Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates
From Insulet Corporation
Via Business Wire
The 3 Best Diabetes Stocks to Buy in June 2024
There's less fear now about weight-loss drugs reducing the need for diabetes devices. Here are three diabetes stocks to buy. 
Via InvestorPlace
NASDAQ:PODD, a strong growth stock, setting up for a breakout.
INSULET CORP (NASDAQ:PODD), a strong growth stock, setting up for a breakout. 
Via Chartmill
Is NASDAQ:PODD suited for growth investing?
INSULET CORP (NASDAQ:PODD) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
4 Analysts Assess Insulet: What You Need To Know
Via Benzinga
7 Stocks That Could Safely 10X by 2030
Unlock the potential for exponential growth with these seven 10x stocks that could skyrocket by 2030 if the stars align. 
Via InvestorPlace
Insulet to Present at the Jefferies Global Healthcare Conference
From Insulet Corporation
Via Business Wire
MicroStrategy Was The Best Among These 10 Large-Cap Stocks Scoring Big Last Week (May 12-May 19, 2024): Are They In Your Portfolio?
Top performing large-cap stocks in the last week: MSTR, MNDY, ONON, SE, PODD, DELL, VOD, ALC, SMCI, CRBG. Analysts raise price targets & more positive news. 
Via Benzinga
Follow the Whales: 3 Genius Stocks the Smart Money Is Piling Into for Triple-Digit Gains
Ride the coattails of institutional investors with these three overlooked stocks smart money investors are piling into for triple-digit gains. 
Via InvestorPlace
Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.
Is INSULET CORP (NASDAQ:PODD) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
Will Insulet's Monopoly Crumble? Appellate Court Ruling Signals Shift in Automated Insulin Delivery Systems Market
Latest on Insulet and its legal battle with EOFlow. Understand the impact of the appellate court's decision on market dynamics and Insulet's future. 
Via Benzinga
Wall Street Trades Flat On Mixed Producer Inflation; Meme Stocks See Wild Ride, Bitcoin Drops: What's Driving Markets Tuesday?
Wall Street is experiencing a subdued trading session, with all major indices showing minimal movement around midday in New York. 
Via Benzinga
Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday?
A worse-than-expected University of Michigan’s May consumer report halted stock gains on Friday, sparking worries about a potential decline in consumer health amid perceived rising price pressures. 
Via Benzinga
Topics Economy
Exposures Interest Rates
PODD Stock Earnings: Insulet Beats EPS, Beats Revenue for Q1 2024
PODD stock results show that Insulet beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year
From Insulet Corporation
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Insulet’s 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth
From Insulet Corporation
Via Business Wire
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment. 
Via InvestorPlace
Topics ETFs
7 Stable Stocks for 50% Returns by Early 2025
These 7 stable stocks also offer 50% returns according to analysts according to analysts tasked with following their respective industries. 
Via InvestorPlace
Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.
INSULET CORP (NASDAQ:PODD)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
From Insulet Corporation
Via Business Wire
Large-Cap Stocks In Trouble: Here Are The 10 Worst Performers Over The Past 12 Months
Over the past 12 months, 10 Large-Cap stocks have underperformed all others. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.